UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 107

Sortiert nach

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Blood, 2017-03, Vol.129 (11), p.1469-1479

2017

Volltextzugriff (PDF)

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Blood, 2018-05, Vol.131 (21), p.2357-2366

2018

Volltextzugriff (PDF)

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study

Clinical cancer research, 2016-04, Vol.22 (7), p.1572-1582

2016

Volltextzugriff (PDF)

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

Haematologica (Roma), 2015-12, Vol.100 (12), p.1571

2015

Volltextzugriff (PDF)

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy

Clinical cancer research, 2016-01, Vol.22 (1), p.86-95

2016

Volltextzugriff (PDF)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia

Journal for immunotherapy of cancer, 2022-01, Vol.10 (1), p.e003392

2022

Volltextzugriff (PDF)

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

Haematologica (Roma), 2009-09, Vol.94 (9), p.1266-1273

2009

Volltextzugriff (PDF)

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib

Blood, 2015-11, Vol.126 (19), p.2213-2219

2015

Volltextzugriff (PDF)

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Blood, 2019-06, Vol.133 (24), p.2575-2585

2019

Volltextzugriff (PDF)

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

Leukemia, 2017-06, Vol.31 (6), p.1340-1347

2017

Volltextzugriff (PDF)

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Leukemia, 2014-11, Vol.28 (11), p.2188-2196

2014

Volltextzugriff (PDF)

Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia

The Journal of immunology (1950), 2018-10, Vol.201 (7), p.1967-1974

2018

Volltextzugriff (PDF)

Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors

Leukemia & lymphoma, 2020-08, Vol.61 (10), p.2375-2382

2020

Volltextzugriff (PDF)

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Blood, 2019-11, Vol.134 (Supplement_1), p.3053-3053

2019

Volltextzugriff (PDF)

Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia

JAMA dermatology (Chicago, Ill.), 2016-06, Vol.152 (6), p.698

2016

Volltextzugriff (PDF)

Prognostic Models Predictive of Disease Progression in CLL Patients Treated with Ibrutinib

Blood, 2016-12, Vol.128 (22), p.187-187

2016

Volltextzugriff (PDF)

Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Blood, 2018-11, Vol.132 (Supplement 1), p.1874-1874

2018

Volltextzugriff (PDF)

Abstract 3756: Highly multiplexed proteomic assessment of the human acute myeloid leukemia bone marrow microenvironment

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3756-3756

2019

Volltextzugriff (PDF)

Atrial Fibrillation in CLL/SLL Patients on Ibrutinib

Blood, 2015-12, Vol.126 (23), p.2933-2933

2015

Volltextzugriff (PDF)

Improving Depth of Response with Continued Ibrutinib Therapy in CLL Patients

Blood, 2017-12, Vol.130, p.4302-4302

2017

Volltextzugriff (PDF)

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Blood, 2018-11, Vol.132 (Supplement 1), p.4424-4424

2018

Volltextzugriff (PDF)

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Blood, 2018-11, Vol.132 (Supplement 1), p.538-538

2018

Volltextzugriff (PDF)

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Blood, 2018-11, Vol.132 (Supplement 1), p.1437-1437

2018

Volltextzugriff (PDF)

1 – 25 von 107

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

ThemaYoung Adult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(92)
Mit Volltextzugriff
(95)

Publikationsform

Artikel
(104)
Berichte
(2)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(49)
Science & Technology
(49)
Humans
(39)
Female
(25)
Male
(25)
Middle Aged
(18)
Aged
(16)
Adult
(15)
Hematology
(12)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(10)
Aged, 80 And Over
(9)
Immunology
(9)
Oncology
(9)
Risk Factors
(9)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Follow-Up Studies
(6)
Pyrazoles - Therapeutic Use
(6)
Pyrimidines - Therapeutic Use
(6)
Infectious Diseases
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study

Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib

Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial

Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia

Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors

Response to the Shingrix Varicella Zoster Virus (VZV) Vaccine in Patients with Chronic Lymphocytic Leukemia (CLL) That Are Treatment Naive or Treated with a Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia

Prognostic Models Predictive of Disease Progression in CLL Patients Treated with Ibrutinib

Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib

Abstract 3756: Highly multiplexed proteomic assessment of the human acute myeloid leukemia bone marrow microenvironment

Atrial Fibrillation in CLL/SLL Patients on Ibrutinib

Improving Depth of Response with Continued Ibrutinib Therapy in CLL Patients

Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)

Eltrombopag for Moderate Aplastic Anemia and Unilineage Cytopenias: Dosing, Long-Term Follow-up, Clonal Evolution and Somatic Mutation Profiling

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Aktive Filter

Suchergebnisse filtern